AI-generated summary
The authors compared daily photobiomodulation therapy with a protocol applied every three days, interspersed with placebo, in 16 patients receiving radiochemotherapy for oral cancer. They report that the alternate-day group had more grade 2 and grade 3 oral mucositis, higher mean pain scores and greater salivary flow reduction, and conclude the daily protocol was more effective. Findings are limited by the small sample.
- Participants
- 16
- Who or what was studied
- Patients diagnosed with oral cancer undergoing radiochemotherapy, divided equally into two groups
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The abstract describes a small sample of 16 patients, and the abstract does not report a formal sample size calculation or confidence intervals for its comparisons.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Preventive Photobiomodulation Therapy (PBMT) significantly reduces oral mucositis (OM) severity in patients undergoing Radiochemotherapy (RCT) for the treatment of oral cancer, but daily applications generate cost, overload the dental team, and reduce the number of patients assisted. To evaluate the effectiveness of two PBMT protocols in preventing OM in patients undergoing RCT for oral cancer.
Material And Methods
16 patients diagnosed with oral cancer undergoing RCT were included, equally divided into two groups: a group treated daily with PBMT, and another group also submitted to daily treatment, however, performing the application of PBMT every three days, interspersed with a simulation of PBMT (placebo). A red laser was used (~660 nm), 0.1W power, 1J of energy applied per point, 9 points per area (labial mucosa, buccal mucosa, lateral borders of the tongue, body of the tongue, and floor of the mouth) from the beginning of RCT until the end of the oncological treatment. Daily assessments were performed regarding OM scores, the World Health Organization (WHO) pain scale, and the visual analog scale (VAS). Weight, salivary flow (SGAPP), OHIP-14, and DMFT were evaluated on the initial and final days of RT. OM incidence and clinical data were compared by Pearson's chi-square test or Fisher's exact test. Pain and other scale scores were compared using the Mann-Whitney and Friedman/Dunn tests (SPSS v20.0 p<0.05).
Results
In the group with PBMT on alternate days, there was an increase in the frequency of grade 2 and grade 3 oral mucositis and an increased risk of grade 2 oral mucositis, in addition to higher mean pain scores and greater reduction in salivary flow.
Conclusions
The daily PBMT protocol proved more effective in controlling the frequency and severity of OM, pain, and salivary flow.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
- Power
- 0.1W
- Total energy
- 1J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Oral mucositis, Photobiomodulation, Randomized controlled trial, GRADE, Visual analogue scale, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.